The factor X assay is a blood test to measure the activity of factor X. This is one of the proteins in the body that helps the blood clot.
Stuart-Prower factor
A blood sample is needed.
You may need to stop taking some medicines before this test. Your health care provider will tell you which ones.
When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.
This test may be used to find the cause of excessive bleeding (decreased blood clotting). The decreased clotting may be caused by an abnormally low level of factor X.
A normal value is 50% to 200% of the laboratory control or reference value.
Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or may test different samples. Talk to your provider about the meaning of your specific test results.
Decreased factor X activity may be related to:
There is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another, and from one side of the body to the other. Obtaining a blood sample from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight, but may include:
This test is most often performed on people who have bleeding problems. The risk of excessive bleeding is slightly greater than for people without bleeding problems.
Gailani D, Benjamin FT, Wheeler AP. Rare coagulation factor deficiencies. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 135.
Ragni MV. Hemorrhagic disorders: coagulation factor deficiencies. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 165.
Sarode R, Kessler CM. Coagulation and fibrinolysis. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 40.
Review Date:
2/2/2023 Reviewed By: Mark Levin, MD, Hematologist and Oncologist, Monsey, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team. |